BCDA

BCDA

USD

BioCardia Inc. Common Stock

$1.330-0.080 (-5.674%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$1.410

最高

$1.410

最低

$1.320

交易量

0.07M

公司基本面

市值

14.1M

行業

生物科技

國家

United States

交易統計

平均交易量

0.60M

交易所

NCM

貨幣

USD

52週範圍

最低 $1當前 $1.330最高 $3.2

相關新聞

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia with a Buy and maintains $25 price target.

查看更多
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target
GlobeNewswire

BioCardia Announces Pricing of Up To $12 Million Public Offering

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA) ("BioCardia" or the "Company"), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and

查看更多
BioCardia Announces Pricing of Up To $12 Million Public Offering
GlobeNewswire

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the

查看更多
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
GlobeNewswire

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today

查看更多
BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025